Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
Umar Jawed, Consultant Haematologist at King’s College Hospital London, Jeddah, shared a post on LinkedIn:
“‘The most dangerous Anti-D result is not the highest one – it’s the one you underestimate early.’
My morning today at King’s College Hospital London – Jeddah started with exactly that.
A routine antenatal screen.
Young patient. Early gestation.
- Anti-D detected.
- Titre: High.
And instantly, what looks like a lab result becomes a time-sensitive fetal risk assessment problem.
Because:
- High-titre Anti-D this early is never reassuring.
It raises one critical question:
Are we already behind in this pregnancy?
The Clinical Shift (Not Just ‘Follow the Titre’)
Following principles from Royal College of Obstetricians and Gynaecologists (RCOG), British Committee for Standards in Haematology (BCSH) and American College of Obstetricians and Gynecologists (ACOG):
This was not a ‘watch and wait’ case.
Management mindset shifted immediately to:
- Early risk stratification
- Urgent fetal medicine referral
- Consideration of fetal RhD genotyping (non-invasive where available)
- Planning for MCA Doppler surveillance
Because once sensitisation is established:
Titre is not the disease – fetal anemia is.
What Makes Anti-D Different
In transfusion medicine, Anti-D is unique:
- Preventable – yet still encountered
- Predictable – yet still underestimated
- Detectable early – but often acted on late
And importantly:
Early high titre is not equal mild disease starting early
It may reflect a sensitised immune system already primed for rapid fetal impact
The Bigger Perspective
This is where transfusion medicine extends beyond the lab.
It becomes:
- Predictive medicine
- Fetal risk stratification
- Multidisciplinary decision-making
Because one antibody, detected at the right time, can completely alter the trajectory of a pregnancy.
Questions for colleagues in transfusion and fetal medicine:
- At what titre (and gestation) do you escalate immediately to fetal medicine?
- Are you routinely integrating non-invasive fetal RhD typing into your pathway?”
Stay updated on Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia